45
What can modelling tell us about HIV and TB that we don’t already know?

What can modelling tell us about HIV and TB that we don’t already know?

Embed Size (px)

Citation preview

What can modelling tell us about HIV and TB that we

don’t already know?

I am not interested in this or that phenomenon, in the spectrum of this or that element. I want to know [God’s] thoughts, the rest are details.

Albert Einstein

Nature only uses the longest threads to weave her patterns, so each small piece of her fabric reveals the organization of the entire tapestry.

Richard Feynman

1. Why is there so much HIV in southern Africa and so little in India and Latin America?

2. Can we control TB without controlling AIDS?

3. Why does survival after infection with HIV vary from months to decades?

4. Is migration important in determining the spread of HIV.

Questions for Einstein

1. Is the prevalence of HIV in Harare really declining at 10% per year?

2. Are CD4 counts a useful measure of immune status for people with HIV?

3. Of TB cases in HIV+ people, what proportion are new and what proportion are reactivations?

4. What is the duration of TB disease in HIV+ and HIV- people?

Questions for Feynman

Theories and models

A model is the expression of a theory

1. Models should be as simple as possible but no simpler.

2. Always start from what is known.

3. Only add complexity as the data or the questions demand it.

15 – 40 5 – 15 1 – 50.5 – 10.1 – 0.50.0 – 0.1 No data

Prevalence of HIV among adults (%)

Highest per capita TB incidence in Africa

25 to 49

50 to 99

100 to 299

< 10

10 to 24

300 or more

No Estimate

per 100 000 population

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

© WHO 2002

Prevalence of HIV in adults (2005)

North India: 0.2%

South India: 1.5%

Brazil: 0.7%

West Africa: 3%

East Africa: 5%

South Africa: 21%

(Median values in Africa)

Kinds of models

1.Dimensional models

2.Analytical models

3.Simple compartmental models

4.Complex compartmental

models

5.Stochastic models

6.Micro-simulation models

7.Network models

Risk factors for HIV infection

Behavioural Number of sexual partners, condom useBiological Other sexually transmitted infections, genderCultural Male circumcision, premarital sexEconomic Poverty and commercial sex workSocial Peer pressure and gender violenceOccupational Truck drivers and mine workers

Risk factors for TB

Behavioural Alcoholism, smokingBiological Gender, possibly race, age, HIVEconomic Poverty, crowding, indoor solid fuelOccupational Silica exposure

Three key concepts

R0: how many people does one person infect?

Generation time T0 : How long does it take?

Steady state P0: Where does it settle down?

0

5

10

15

20

25

30

1990 1995 2000 2005

HIV

pre

vale

nce

(%)

ANC women in South Africa

Doubling time = 15 months

R0 = 120/15 = 8

e( )

1 e

t

t

aP t

1. Grosskurth, H., et al., Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet, 1995. 346: p. 530-6.2. Laga, M. STD control for HIV prevention--it works! Lancet, 1995. 346: p. 518-9.

Syndromic management of sexually transmitted diseases, Mwanza, Tanzania

Prevalence of STIs ~ 10%Curable STIs increase transmission ~ 5 timesSTIs increase HIV incidence by 0.15+0.91 = 1.4 times

Measured incidence in two groups of villages

Control: 0.9%/yr Intervention: 0.6%/yr

Ratio: 1.6 (1.2–2.2)1

It works!2

Mwanza: Grosskurth, H., et al., Lancet, 1995Rakai: Wawer, M.J., et al., Lancet, 1999Masaka: Kamali, A., et al., Lancet, 2003

Control Interv. Ratio

Mwanza (SM) 0.9 0.6 1.61 (1.18–2.22)Rakai (MT) 1.5 1.5 1.03 (0.86–1.23)Masaka (IEC+SM) 0.8 0.8 1.00 (0.63–1.59)

SM: syndromic management; MT: mass treatment; IEC: information, education and counselling.

Three trials0.4

0.6

0.8

1.0

1.2

1.4

1.6

Mwanza(SM)

Rakai(MT)

Masaka(IEC+SM)

STDSim: Micro-simulation model

•Individual based•Stochastic•Health care•STI natural history and transmission•Sexual behaviour•Demography•Interventions

Richard White’s conclusion

…in widely disseminated HIV epidemics … STI treatment may [not be an] effective HIV prevention strategy. In less advanced … HIV epidemics [it may be an] effective … strategy, and it remains useful … in sub-populations with very high rates of STIs, such as sex workers, their clients and regular partners.

Richard White Variability in the effectiveness of STI treatment interventions to prevent HIV transmission in Eastern and Southern Africa, Ph.D. Thesis. LSHTM, 2006

0

5

10

15

20

1970 1990 2010 2030

Pre

vale

nce

(%)

ANC women

Behaviour change in Uganda

= birth rate

N = S + I

= rate at which new infections occur

= mortality

S I

I N SI /N I

S

The basic model

0

20

40

60

80

100

1970 1990 2010 2030

Pre

vale

nce

(%)

012345678910

Inci

denc

e/M

orta

lity

(%/y

r)

ANC women in Uganda

R0 = 3.3

0

0

-1=70%

R

R

= birth rate

N = S + I

= infection rate

I = Weibull mortality

S I

I N SI /N I

S

0.0

0.2

0.4

0.6

0.8

1.0

0 10 20 30Time (years)

P(s

urv

ivin

g)

Normal (Weibull 2)

Exponential(Weibull 1)

0

20

40

60

80

1970 1990 2010 2030

Pre

vale

nce

(%)

0

2

4

6

8

10

12

Inci

denc

e/M

orta

lity

(%/y

r)

ANC women in Uganda

= birth rate

N = population = e–P

I = Weibull mort.

~

~

S I

I N S I /N I S

0.0

0.2

0.4

0.6

0.8

1.0

0 10 20 30Prevalence (%)

Re

lativ

e t

ran

smis

sio

n

.

–Pe

Heterogeneity in sexual behaviour

0

5

10

15

1970 1990 2010 2030

Pre

vale

nce

(%)

0

1

2

Inci

denc

e/M

orta

lity

(%/y

r)

ANC women in Uganda

0.0

0.2

0.4

0.6

0.8

1.0

1985 1990 1995 2000Year

Re

lativ

e t

ran

smis

sio

n

.

~

S I

I N SI /N I

S ~

= birth rate

N = population = C(t)

I = mortality

~

~

C(t)

Including control

0

5

10

15

1970 1990 2010 2030

Pre

vale

nce

(%)

0

1

2

Inci

denc

e/M

orta

lity

(%/y

r)

ANC women in Uganda

~

S I

I N SI /N I

S *

= birth rate

N = population = e

I = mortality

~

* –M

0.0

0.2

0.4

0.6

0.8

1.0

0 2 4Annual mortality (%)

Re

lativ

e t

ran

smis

sio

n

. –Me

Mortality leads to behaviour change

0

5

10

15

1970 1990 2010 2030

Pre

vale

nce

(%)

0

1

2

Inci

denc

e/M

orta

lity

(%/y

r)

ANC women in Uganda

Nairobi

6 yr

Nunn P et al. Tuberculosis control in the era of HIV. Nat Rev Immunol. 2005 Oct;5(10):819-26.

9.4

1.11.11.0

5.9

2.2

0

2

4

6

8

10

1991-1994 1995-1997 1998-1999

Ann

ual in

ciden

ce (

%)

.HI V- HI V+

TB incidence among gold miners in SACorbett EL Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis. 2003;188: 1156-63.

SS+ Tuberculosis

Prevalence Incidence Disease Duration

(%) (%/yr) (yr)

HIV+ 0.44 (0.02-1.05) 2.87 (1.94-4.25) 0.15 (0.05-0.48)

HIV- 0.55 (0.14–0.95) 0.48 (0.27-0.84) 1.15 (0.48-1.13) DDR = 0.13 (0.09–0.20)

Gold miners in South Africa

We define disease duration as prevalence divided by incidence

Repeat the model 4 times, once for each stage of HIV. Use time series of HIV prevalence to determine incidence. Incidence gives rate at which people enter first stage; overall (Weibull) survival determines rate at which people move to next stage.

TB-HIV model

Williams BG et al. The impact of HIV/AIDS on the control of tuberculosis in India. PNAS 2005 102: 9619-9624.

Impact of interventions on TB cases in KenyaT

B in

cide

nce/

100k

/yr

800

600

400

200

0

.Baseline

ARV 80%

TLTI (6 m)

TLTI (life)

ARV 100%

TB detect.

TB cure

HIV incid

Base line:CDR = 50%CR = 70%Interventions:1% increase

1980 2000 2020 2040 Year

Currie, C. et al. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC, 2005. 5: 130.

Percent Percent HIV positive HIV negative

Williams BG et al. HIV Infection, Antiretroviral Therapy, and CD4+ Cell Count Distributions in African Populations. J Infect Dis, 2006 194: 1450-8.

1,000

2,000

10 20

Time to death (yrs)

Initi

al C

D4/

L

Time to death (yrs)

1,000

2,000

10 20

Initi

al C

D4/

L

Model 1

CD4 decline independent of starting value

Survival determined by pre-infection CD4

Model 2

Survival independent of starting value

CD4 decline determine entirely by starting value and survival distribution

Spatial Epidemiology of HIV

Doubling time = 1 yearLife expectancy = 10 yearsNumber of partners = 4

Proportion of random partners chosen at random = 0 (left hand set) or 10% (right hand set) in the following slides.

Note that in this model migrants have exactly the same sexual behaviour and individual risk as non-migrants.

1. Can we combine spatial/network models with our more conventional continuous time models of HIV?

2. Can we get a better understanding of the host-viral interaction?

3. What are the population level implications of 2?

4. Do we have enough data to explore fully the joint dynamics of TB and HIV?

Questions for all of us

Advice to young epidemiologists

Never make a calculation until you know the answer. Make an estimate before every calculation,

try a simple biological argument (R0, generation time, selection, survival, control). Guess the answer to every puzzle. Courage: no one else needs to know what the guess is. Therefore, make it quickly, by instinct. A right guess reinforces this instinct. A wrong guess brings the refreshment of surprise. In either case, life as an epidemiologist, however long, is more fun.

Plagiarised from E.F. Taylor and J.A. Wheeler Space-time Physics 1963